1-methyl-3-ethyl>carbamoyl>-1,4-dihydropyridine | 84455-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-methyl-3-ethyl>carbamoyl>-1,4-dihydropyridine
• 英文别名: 1-methyl-3-{{N-{β-[3,4-bis(pivalyloxy)phenyl]ethyl}carbamoyl}}-1,4-dihydropyridine；1-methyl-3-{N-[β-(3,4-dipivalyloxyphenyl)ethyl]}-carbamoyl-1,4-dihydropyridine；1-Methyl-3-{N-[beta-(3,4-dipivalyloxyphenyl)ethyl]}carbamoyl-1,4-dihydropyridine；[2-(2,2-dimethylpropanoyloxy)-4-[2-[(1-methyl-4H-pyridine-3-carbonyl)amino]ethyl]phenyl] 2,2-dimethylpropanoate
• CAS: 84455-04-9
• 化学式: C₂₅H₃₄N₂O₅
• 分子量: 442.555
• InChiKey: DHLMADRPASTSDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-methyl-3-ethyl>carbamoyl>-1,4-dihydropyridine 、 CDCl3 D2O 、 、 生成 1-methyl-3-carbamoyl>-1,4-dihydropyridine
  参考文献：
  名称：

  Brain-specific dopaminergic activity involving dihydropyridine

  摘要：

  在需要这种治疗的患者（例如，帕金森病或高催乳素血症患者）中，通过向其施用治疗有效量的优选儿茶酚保护的多巴胺，该多巴胺与一种还原的、穿过血脑屏障的脂质形式[D-DHC]的吡啶鎓盐型氧化还原载体，例如1,4-二氢三甲基咖啡碱。体内二氢吡啶载体基团的氧化形成离子型吡啶鎓盐型多巴胺/载体实体[D-QC] +，防止其从大脑中消除，同时加速从全身循环中的消除，导致显著且持续时间长的大脑特异性多巴胺能活性。

  公开号：

  US04727079A1
• 作为产物：
  描述：

  1-methyl-3-ethyl>carbamoyl>pyridinium iodide 生成 1-methyl-3-ethyl>carbamoyl>-1,4-dihydropyridine
  参考文献：
  名称：

  BODOR, NICHOLAS S.

  摘要：

  DOI：

文献信息

• Improved delivery through biological membranes. 13. Brain-specific delivery of dopamine with a dihydropyridine .dblharw. pyridinium salt type redox delivery system
  作者：Nicholas Bodor、Hassan H. Farag

  DOI：10.1021/jm00358a013

  日期：1983.4

  The dihydropyridine in equilibrium with pyridinium salt type redox delivery system was used for the brain-specific delivery of dopamine. In vivo administration of the catechol-protected dopamine coupled with 1,4-dihydrotrigonelline as the carrier resulted in brain-specific, high and sustained concentrations of the 1-methyl-3-[N-[beta-(3,4-dihydroxyphenyl)ethyl]carbamoyl]pyridinium salt, the direct

  与吡啶鎓盐型氧化还原递送系统平衡的二氢吡啶用于脑特异性递送多巴胺。体内施用邻苯二酚保护的多巴胺与1,4-二氢甘油三苯胺作为载体，导致大脑特异性，高浓度和持续浓度的1-甲基-3- [N-β-（3,4-二羟基苯基）多巴胺的直接前体乙基] [氨基甲酰基]吡啶鎓盐在大脑中锁定了多个小时，而全身浓度迅速下降，不到30分钟以1/2的速度下降。在大脑中观察到了明显的多巴胺能活性，持续了几个小时。
• Brain-specific drug delivery of steroid sex hormones cleaved from
  申请人：University of Florida

  公开号：US04900837A1

  公开（公告）日：1990-02-13

  The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are: (a) compounds of the formula [D--DHC] (I) wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine.revreaction.pyridinium salt redox carrier, with the proviso that when [DHC] is ##STR1## wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH function group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alkanol; and (b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine.revreaction.pyridinium salt redox carrier. The corresponding ionic pyridinium salt type drug/carrier entitles [D--QC].sup.+ X.sup.- are also disclosed.

  这些化合物适用于特定部位/持续性地将中枢神经系统药物物种传递到大脑，其中包括：（a）公式[D--DHC]（I）的化合物，其中[D]是中枢神经系统药物物种，[DHC]是二氢吡啶盐氧化还原载体的还原、可生物氧化、穿过血脑屏障的脂质形式，但当[DHC]为##STR1##其中R为低级烷基或苄基，[D]为含有单个NH.sub.2或OH官能团的药物物种，当存在单个OH官能团时，其为一级或二级OH官能团，该药物物种通过NH.sub.2或OH功能团直接连接到[DHC]的羰基功能团，则[D]必须不是交感神经兴奋剂、类固醇性激素或长链烷醇；以及（b）公式（I）的化合物的非毒性药用可接受盐，其中[D]是中枢神经系统药物物种，[DHC]是二氢吡啶盐氧化还原载体的还原、可生物氧化、穿过血脑屏障的脂质形式。还公开了相应的离子吡啶盐型药物/载体[D--QC].sup.+ X.sup.-。
• Brain-specific dopaminergic activity involving dihydropyridine
  申请人：University of Florida

  公开号：US04727079A1

  公开（公告）日：1988-02-23

  A brain-specific dopaminergic response is elicited in a patient in need of such treatment, e.g., a patient afflicted with Parkinson's disease of hyperprolactinemia, by administering thereto a therapeutically effective amount of preferably catechol protected dopamine tethered to a reduced, blood-brain barrier penetrating lipoidal form [D-DHC] of a dihydropyridine.revreaction.pyridinium salt type redox carrier, e.g., 1,4-dihydrotrigonelline. Oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt type dopamine/carrier entity [D-QC].sup.+ prevents elimination thereof from the brain, while elimination from the general circulation is accelerated, resulting in significant and prolongedly sustained brain-specific dopaminergic activity.

  在需要这种治疗的患者（例如，帕金森病或高催乳素血症患者）中，通过向其施用治疗有效量的优选儿茶酚保护的多巴胺，该多巴胺与一种还原的、穿过血脑屏障的脂质形式[D-DHC]的吡啶鎓盐型氧化还原载体，例如1,4-二氢三甲基咖啡碱。体内二氢吡啶载体基团的氧化形成离子型吡啶鎓盐型多巴胺/载体实体[D-QC] +，防止其从大脑中消除，同时加速从全身循环中的消除，导致显著且持续时间长的大脑特异性多巴胺能活性。
• Brain-specific delivery of dopamine utilizing dihydropyridine/pyridinium
  申请人：University of Florida

  公开号：US04880816A1

  公开（公告）日：1989-11-14

  A brain-specific dopaminergic response is elicited in a patient in need of such treatment, e.g., a patient afflicted with Parkinson's disease of hyperprolactinemia, by administering thereto a therapeutically effective amount of preferably catechol protected dopamine tethered to a reduced, blood-brain barrier penetrating lipoidal form [D-DHC] of a dihydropyridine.revreaction.pyridinium salt type redox carrier, e.g., 1,4-dihydrotrigonelline. Oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt type dopamine/carrier entity [D-QC].sup.+ prevents elimination thereof from the brain, while elimination from the general circulation is accelerated, resulting in significant and prolongedly sustained brain-specific dopaminergic activity.

  在需要此类治疗的患者身上，例如患有帕金森病或高泌乳素血症的患者，通过向其施用治疗有效量的优选儿茶酚保护的多巴胺，该多巴胺与一种还原的、能穿过血脑屏障的脂质形式[D-DHC]的二氢吡啶盐型氧化还原载体，例如1,4-二氢三甲基咖啡碱结合。体内二氢吡啶载体基团的氧化形成离子型吡啶盐型多巴胺/载体实体[D-QC]sup.+，防止其从大脑中消失，同时加速其从全身循环中消除，从而导致显著且长期持续的大脑特异性多巴胺能活性。
• Pharmaceutical formulations for parenteral use
  申请人：UNIVERSITY OF FLORIDA

  公开号：EP0335545A2

  公开（公告）日：1989-10-04

  Aqueous parenteral solutions of drugs which are insoluble or only sparingly'soluble in water and/or which are unstable in water, combined with a hydroxypropyl,hydroxyethyl, glucosyl, maltosyl or maltotriosyl derivative of 3-or γ-cyclodextrin, provide a means for alleviating problems associated with drug precipitation at the injection site and/or in the lungs or other organs following parenteral administration.

  不溶于水或只能少量溶于水和/或在水中不稳定的药物的肠外水溶液与 3-或 γ-环糊精的羟丙基、羟乙基、葡糖基、麦芽糖基或麦芽三糖基衍生物结合使用，可以缓解肠外给药后药物在注射部位和/或肺部或其他器官沉淀的问题。